Product Center
Influenza Virus Subunit Vaccine Application Accepted!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-07
- Views:
(Summary description)On June 7, 2024, Ab&B Bio-Tech Co., Ltd. (JS) (hereinafter referred to as "Ab&B Bio") announced that the application for its "Influenza Virus Subunit Vaccine" was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China.
Influenza Virus Subunit Vaccine Application Accepted!
(Summary description)On June 7, 2024, Ab&B Bio-Tech Co., Ltd. (JS) (hereinafter referred to as "Ab&B Bio") announced that the application for its "Influenza Virus Subunit Vaccine" was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-07 14:01
- Views:
On June 7, 2024, Ab&B Bio-Tech Co., Ltd. (JS) (hereinafter referred to as "Ab&B Bio") announced that the application for its "Influenza Virus Subunit Vaccine" was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China.

Source: Official Website of the Center for Drug Evaluation, NMPA
At present, the influenza virus remains one of the most important respiratory pathogens threatening public health. Seasonal influenza outbreaks or occasional cross-species transmission of influenza viruses and pandemics have significant impacts on human health and socioeconomic development. The WHO position paper on influenza vaccination and the Chinese CDC's Technical Guidelines for Influenza Vaccination in China (2023-2024) clearly state that annual influenza vaccination is the most cost-effective preventive measure, which can significantly reduce the risk of influenza and serious complications.
This year, WHO noted that since March 2020, the global influenza surveillance network has not detected the B/Yamagata virus, and therefore recommended removing the B/Yamagata lineage component from influenza vaccines. Ab&B Bio responded promptly and initiated the regulatory submission for its influenza virus subunit vaccine to accelerate product launch, thereby supporting scientific influenza prevention and control efforts and expanding vaccine options for the public.
Ab&B Bio has always focused on innovation rather than imitation, dedicating itself to subunit influenza vaccine technology. To date, Ab&B Bio's subunit influenza vaccine portfolio includes: quadrivalent influenza virus subunit vaccine for individuals aged 6-35 months, quadrivalent influenza virus subunit vaccine for individuals aged 3 years and older, adjuvanted quadrivalent influenza virus subunit vaccine for the elderly, trivalent influenza virus subunit vaccine, adjuvanted trivalent influenza virus subunit vaccine for the elderly, as well as other subunit influenza vaccines in development. These products precisely address the needs of diverse populations. Among them, the quadrivalent influenza virus subunit vaccine (HRK-X®) for individuals aged 3 years and older has been commercially available, gaining positive feedback for its high purity, low reactogenicity, excellent safety, and broad protection. Ab&B Bio will continue to uphold innovation-driven strategies and quality leadership, aiming to launch all its influenza vaccine products expeditiously and further contribute to influenza prevention and control with cutting-edge solutions!
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us